RECOVERY & TISSUE REPAIR / MATRIX
Three Peptides, Three Very Different Evidence Bases
How BPC-157, TB-500, and KLOW differ in mechanism, evidence maturity, regulatory standing, and what each caution actually means for load-bearing tissue.
The short version
This page lines up BPC-157, TB-500, and KLOW on the dimensions that matter most for reading recovery-and-tissue-repair peptide research through a high-performance, return-to-play lens: mechanism, evidence maturity, regulatory and anti-doping status, and the single most important caution for each. The short version: all three are studied for tissue repair, but their evidence bases are very different in size and kind, none is an approved medicine, and two of the three — with the blend implicated through one of its components — are banned in competitive sport. Nothing here is a recommendation.
The comparison matrix
| Dimension | BPC-157 | TB-500 | KLOW |
|---|---|---|---|
| What it is | Stable 15-amino-acid gastric-derived peptide | Synthetic 7-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4 | Four-peptide research vial: KPV + GHK-Cu + BPC-157 + TB-500 |
| Primary mechanism | VEGFR2-Akt-eNOS angiogenesis [4] | Actin sequestration, cell migration (strongest data on full-length protein) [8][10] | Combines the other three's mechanisms plus KPV's anti-inflammatory signaling [15] |
| Human evidence | One 2-person IV safety pilot [1] | One Phase 1 trial, but of the full-length protein, not the fragment [9] | None — the blend has never been tested [6][9] |
| Evidence maturity | Overwhelmingly rodent; 3 small human pilots as of 2025 [2] | Overwhelmingly rodent/cell for the fragment; human data exist only for the parent protein [6][9] | Single-component evidence only; zero blend-level studies |
| Regulatory status | Not FDA-approved; research use only | Not FDA-approved; research use only | Not FDA-approved; research use only |
| WADA status | Prohibited (S0, non-approved substances) | Prohibited (peptide / growth-factor category) [6] | Implicated via its TB-500 component [6][9] |
| Key caution | Thin human evidence, largely from one research group [2] | Fragment vs. full-protein identity confusion — most efficacy data is for a different molecule [8] | No study of the combination itself; components clear at mismatched rates [3][9] |
Mechanism
BPC-157's best-supported mechanism is angiogenesis through VEGFR2-Akt-eNOS signaling — new blood-vessel growth that speeds tissue's access to oxygen and nutrients during repair [4]. TB-500's mechanism is different in kind: it is built around actin sequestration and cell migration, the process cells use to move into and remodel injured tissue [10] — though this mechanism is best documented for the full-length thymosin beta-4 protein, not the short fragment actually sold as TB-500 [8]. KLOW adds two more mechanisms on top of both — GHK-Cu's broad transcriptomic shift toward matrix synthesis and antioxidant defense [13], and KPV's suppression of NF-kB inflammatory signaling [15] — with the explicit caveat that no study has confirmed these four mechanisms actually combine the way the rationale suggests.
Evidence maturity
This is where the three separate most clearly. BPC-157 has the most human data of the three, but it is still just one two-person IV safety pilot layered on top of decades of rodent cytoprotection and angiogenesis work [1][2][4][5]. TB-500's human evidence is a genuine identity puzzle: a solid Phase 1 safety trial exists, but it tested the full-length parent protein, not the short fragment sold commercially, so it cannot be read as direct safety evidence for TB-500 itself [9]. KLOW has no blend-level evidence at all — every claim about it rests on extrapolating from research on its four components studied separately [1][6][13][14][15].
Regulatory and anti-doping status
None of the three is an approved medicine anywhere; all are sold strictly for laboratory research use. BPC-157 is prohibited at all times in competitive sport under the World Anti-Doping Agency's non-approved-substances category. TB-500 is prohibited under WADA's peptide and growth-factor category, and anti-doping laboratories have developed detection methods for it [6]. Because TB-500 is one of KLOW's four components, using the blend implicates the same anti-doping rules regardless of intent [6][9].
Key caution
Each compound carries a defining caveat. For BPC-157 it is how thin the human evidence still is, and how much of the foundational literature traces back to one research group, limiting independent replication [2]. For TB-500 it is the fragment-versus-full-protein identity confusion — most of the encouraging efficacy literature was never run on the molecule actually sold under that name [8]. For KLOW it is simpler still: no controlled study has ever tested the four-peptide combination, and a pharmacokinetic mismatch between its fast-clearing and slow-clearing components is built into the formulation itself [3][9]. Read together, the pattern across the three is: more components does not mean more evidence — it means more extrapolation.